BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 23700057)

  • 21. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
    Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
    Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J
    Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
    Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
    Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
    Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G; v Stackelberg A; Eckert C
    Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
    Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
    Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
    Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
    Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
    Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
    Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
    Pichler H; Möricke A; Mann G; Teigler-Schlegel A; Niggli F; Nebral K; König M; Inthal A; Krehan D; Dworzak MN; Janousek D; Harbott J; Schrappe M; Gadner H; Strehl S; Haas OA; Panzer-Grümayer R; Attarbaschi A;
    Br J Haematol; 2010 Apr; 149(1):93-100. PubMed ID: 20067563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
    Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
    Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and implications for follow-up.
    Krappmann P; Paulides M; Stöhr W; Ittner E; Plattig B; Nickel P; Lackner H; Schrappe M; Janka G; Beck JD; Langer T
    Pediatr Hematol Oncol; 2007 Mar; 24(2):101-9. PubMed ID: 17454775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
    Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
    Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
    Dunphy CH; Kitchen S; Saravia O; Velasquez WS
    Am J Hematol; 1996 Jan; 51(1):85-9. PubMed ID: 8571944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.